2018 Third Annual Oncology Guide to New FDA Approvals

FDA Updates

Welcome to the Third Annual Oncology Guide to New FDA Approvals

FDA Updates

FDA Approvals in 2017 Represent a 21-Year High

Gary M. Owens, MD

FDA Updates

FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017

FDA Updates, Lung Cancer

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Lymphoma

Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Lymphoma

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Bladder Cancer

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Breast Cancer

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Leukemia

Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy

Loretta Fala, Medical Writer

FDA Updates, Multiple Myeloma

Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

1
2

Page 1 of 2
Results 1 - 10 of 15

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.